Literature DB >> 3550070

Membrane attack complex of complement in rheumatoid synovial tissue demonstrated by immunofluorescent microscopy.

M E Sanders, J A Kopicky, F M Wigley, M L Shin, M M Frank, K A Joiner.   

Abstract

Rheumatoid and osteoarthritic synovial membranes were examined for evidence of terminal complement pathway activation. Using antiserum highly specific for C9 neoantigen, immunofluorescent microscopy was employed to study synovial membrane specimens from 4 patients with rheumatoid arthritis, one patient with psoriatic arthritis, and 5 patients with osteoarthritis. C9 neoantigen was detected in 3 of the 4 rheumatoid membranes, the one psoriatic membrane, and one of the 5 osteoarthritic membranes. Activation of the terminal pathway of complement through C9 should be added to the spectrum of immunologic events known to occur in some rheumatoid synovial membranes.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3550070

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  11 in total

1.  Detection of the terminal fluid-phase complement complex, SC5b-9, in the plasma of patients with insulin-dependent (type I) diabetes mellitus. Relation to increased urinary albumin excretion and plasma von Willebrand factor.

Authors:  G Triolo; E Giardina; D Casiglia; G Scarantino; G D Bompiani
Journal:  Clin Exp Immunol       Date:  1991-04       Impact factor: 4.330

2.  Human rheumatoid synovial cell stimulation by the membrane attack complex and other pore-forming toxins in vitro: the role of calcium in cell activation.

Authors:  R H Daniels; B D Williams; B P Morgan
Journal:  Immunology       Date:  1990-11       Impact factor: 7.397

3.  Modulation of PBMC-decay accelerating factor (PBMC-DAF) and cytokines in rheumatoid arthritis.

Authors:  Roma Pahwa; Uma Kumar; Nibhriti Das
Journal:  Mol Cell Biochem       Date:  2016-02-23       Impact factor: 3.396

4.  Complement in acute and chronic arthritides: assessment of C3c, C9, and protectin (CD59) in synovial membrane.

Authors:  Y T Konttinen; A Ceponis; S Meri; A Vuorikoski; P Kortekangas; T Sorsa; A Sukura; S Santavirta
Journal:  Ann Rheum Dis       Date:  1996-12       Impact factor: 19.103

Review 5.  Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects.

Authors:  B P Morgan
Journal:  Biochem J       Date:  1989-11-15       Impact factor: 3.857

Review 6.  Membrane attack by complement: the assembly and biology of terminal complement complexes.

Authors:  Cosmin A Tegla; Cornelia Cudrici; Snehal Patel; Richard Trippe; Violeta Rus; Florin Niculescu; Horea Rus
Journal:  Immunol Res       Date:  2011-10       Impact factor: 2.829

7.  Stimulation of human rheumatoid synovial cells by non-lethal complement membrane attack.

Authors:  R H Daniels; W A Houston; M M Petersen; J D Williams; B D Williams; B P Morgan
Journal:  Immunology       Date:  1990-02       Impact factor: 7.397

8.  Activation of terminal components of complement in patients with Guillain-Barré syndrome and other demyelinating neuropathies.

Authors:  C L Koski; M E Sanders; P T Swoveland; T J Lawley; M L Shin; M M Frank; K A Joiner
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

9.  Toxicity of complement for chondrocytes. A possible source of cartilage degradation in inflammatory arthritis.

Authors:  S Satsuma; R A Scudamore; T D Cooke; W P Aston; R Saura
Journal:  Rheumatol Int       Date:  1993       Impact factor: 2.631

10.  Apoptosis is associated with reduced expression of complement regulatory molecules, adhesion molecules and other receptors on polymorphonuclear leucocytes: functional relevance and role in inflammation.

Authors:  J Jones; B P Morgan
Journal:  Immunology       Date:  1995-12       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.